---
schema_version: "secwatch.filing_event.v1"
accession: "0001764013-23-000097"
form_type: "8-K"
ticker: "IMVT"
cik: "0001764013"
company_name: "Immunovant, Inc."
filed_at: "2023-08-23T23:59:59+00:00"
generated_at: "2026-06-11T04:54:20.847396+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.15
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Immunovant shareholders elect three directors, ratify EY, approve exec compensation

## Summary
- Peter Salzmann (98.5M for, 17.7M withheld), Douglas Hughes (96.6M for, 19.6M withheld), George Migausky (96.6M for, 19.7M withheld) elected to board.
- Ratification of Ernst & Young as independent auditor for FY2024: 121,206,460 for, 5,261 against, 1,355 abstain.
- Non-binding advisory approval of named executive officer compensation: 115,397,185 for, 825,452 against, 8,173 abstain, 4,982,266 broker non-votes.
- Annual meeting turnout ~93% of outstanding shares (121,213,076 shares represented).
- All three proposals passed; no material changes to governance disclosed.

## SEC filing metadata
- accession: 0001764013-23-000097
- form_type: 8-K
- ticker: IMVT
- cik: 0001764013
- company_name: Immunovant, Inc.
- filed_at: 2023-08-23T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.15
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1764013/000176401323000097/0001764013-23-000097-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1764013/000176401323000097/imvt-20230821.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001764013-23-000097
- JSON: https://secwatch.observer/filing/0001764013-23-000097.json
- Plain text: https://secwatch.observer/filing/0001764013-23-000097.txt

## Key facts
- Shareholder Votes
  Immunovant, Inc. shareholders approved Approval, on a Non-Binding Advisory Basis, of the Compensation of Immunovant’s Named Executive Officers at the 2023-08-21 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2023-08-21
  source text: Proposal 3- Approval, on a Non-Binding Advisory Basis, of the Compensation of Immunovant’s Named Executive Officers The stockholders approved, on a non-binding advisory basis, the compensation of Immunovant's named executive officers, as disclosed in the Proxy Statement, including the compensation tables and related narrative disclosures, by the following votes: Votes For Votes Against Votes Abstain Broker Non-Votes 115,397,185 825,452 8,173 4,982,266
  evidence_url: https://www.sec.gov/Archives/edgar/data/1764013/000176401323000097/0001764013-23-000097-index.htm
- Shareholder Votes
  Immunovant, Inc. shareholders approved Ratification of the Selection of Ernst & Young LLP as Independent Registered Public Accounting Firm at the 2023-08-21 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-08-21
  source text: Proposal 2 – Ratification of the Selection of Independent Registered Public Accounting Firm The stockholders ratified the selection by the Audit Committee of the Board of Ernst & Young LLP as Immunovant’s independent registered public accounting firm for the year ending March 31, 2024, by the following votes: Votes For Votes Against Votes Abstain 121,206,460 5,261 1,355
  evidence_url: https://www.sec.gov/Archives/edgar/data/1764013/000176401323000097/0001764013-23-000097-index.htm
- Shareholder Votes
  Immunovant, Inc. shareholders approved Election of Peter Salzmann, M.D., M.B.A., Douglas Hughes and George Migausky as directors at the 2023-08-21 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-08-21
  source text: Proposal 1 – Election of Directors Peter Salzmann, M.D., M.B.A., Douglas Hughes and George Migausky were each elected to serve as a member of Immunovant’s Board of Directors, or the Board, until the 2024 Annual Meeting of Stockholders and until his successor is duly elected and qualified, or until his earlier death, resignation or removal, by the following votes: Nominee Votes For Votes Withheld Broker Non-Votes Peter Salzmann, M.D., M.B.A. 98,532,525 17,698,285 4,982,266 Douglas Hughes 96,590,902 19,639,908 4,982,266 George Migausky 96,550,901 19,679,909 4,982,266
  evidence_url: https://www.sec.gov/Archives/edgar/data/1764013/000176401323000097/0001764013-23-000097-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.